Glancy prongay & murray llp commences investigation on behalf of acorda therapeutics, inc. investors (acor)

Los angeles--(business wire)--glancy prongay & murray llp (“gpm”) announces an investigation on behalf of acorda therapeutics, inc. (“acorda” or the “company”) (nasdaq: acor) investors concerning the company and its officers’ possible violations of federal securities law. to obtain information or aid in the investigation, please visit the acorda investigation page on our website at www.glancylaw.com/case/acorda-therapeutics-inc. on november 15, 2017, acorda announced that five patients enrolled in a late stage trial of tozadenant, a treatment for parkinson’s, had died. on this news, acorda’s share price fell $11.20, or 39.7%, to close at $17.00 on november 15, 2017, thereby injuring investors. follow us for updates on twitter: twitter.com/gpm_llp. if you purchased acorda securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact lesley portnoy, esquire, of gpm, 1925 century park east, suite 2100, los angeles, california 90067 at 310-201-9150, toll-free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. if you inquire by email please include your mailing address, telephone number and number of shares purchased. this press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules.
ACOR Ratings Summary
ACOR Quant Ranking